Three-Year Outcomes Reported by Patients Using Bimekizumab for Plaque Psoriasis: Findings from the BE RADIANT Randomized Trial - Top-Institutions - MDSpire

Three-Year Outcomes Reported by Patients Using Bimekizumab for Plaque Psoriasis: Findings from the BE RADIANT Randomized Trial

  • By

  • Matthias Augustin

  • Steven R. Feldman

  • Richard B. Warren

  • April Armstrong

  • Ronald Vender

  • Anna López-Ferrer

  • William H. Dawe

  • Jérémy Lambert

  • Balint Szilagyi

  • Bengt Hoepken

  • Rhys Warham

  • Alice B. Gottlieb

  • April 1, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Dermatology
    • Rheumatology
    • Clinical Research

  • #3

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Dermatology
    • Immunodermatology
    • Clinical Trials

  • #4

    Massachusetts General Hospital (MGH)
    Massachusetts General Hospital (MGH)

    Boston, MA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

  • #5

    Stanford University Medical Center
    Stanford University Medical Center

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

Original Source(s)

Three-Year Outcomes Reported by Patients Using Bimekizumab for Plaque Psoriasis: Findings from the BE RADIANT Randomized Trial

  • by Matthias Augustin, Steven R. Feldman, Richard B. Warren, April Armstrong, Ronald Vender, Anna López-Ferrer, William H. Dawe, Jérémy Lambert, Balint Szilagyi, Bengt Hoepken, Rhys Warham, Alice B. Gottlieb

  • April 1, 2026

Related Content

A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer’s Disease?

Navigating renal safety in the biologic treatment of psoriasis: from immunologic mechanisms to clinical practice

Paradoxical inflammatory switches during biologic therapy: a mechanistic framework, clinical algorithm, and pediatric illustrations